NEWS & EVENTS
THE LATEST ON PMT
PMT Partners announced that the FDA and CE-Mark cleared AirTight Control Syringe was approved for sale, and the company began shipping product on August 14, 2019. The AirTight Control Syringe is intended to inject contrast media or saline during angiographic procedures and offers substantial improvements in injection ergonomics and patient safety as compared to fixed and rotating-luer control syringes commonly used for angiographic injection today.
While fixed-luer syringes offer secure, leak-free connections to catheters and manifolds, their solid, one-piece design makes this connection and disconnection awkward for clinicians.
Rotating-luer syringes have an integrated O-ring design that makes them easier to connect and disconnect, but they are prone to loose, wobbly connections and air leakage, putting patients at risk of air embolism.
The patented AirTight Syringe Control Syringe bridges the gap between fixed and rotating luer angiographic control syringes, offering easy connection and disconnection to catheters and manifolds without compromising patient safety.
PMT Partners' AirTight Platform is protected by U.S. patents 10,207,057; 10,058,656; and other U.S. and foreign pending and issued patents.
For more information about PMT Partners and the company's AirTight Platform, call 1-954-534-9345 or visit www.powrsyringe.com.
AirTight Control Syringe Cleared for Sale
August 14-17, 2019
Visit PMT at AMP Symposium 2019
September 7-10, 2019
Visit PMT at CIRSE 2019
Visit PMT at LINC 2020
January 28-31, 2020